Compare AEHL & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | LYRA |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.6M |
| IPO Year | 2007 | 2020 |
| Metric | AEHL | LYRA |
|---|---|---|
| Price | $0.94 | $1.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 2.9M | 129.9K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,773,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.99 | N/A |
| 52 Week Low | $1.01 | $1.63 |
| 52 Week High | $8.42 | $37.50 |
| Indicator | AEHL | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 28.60 |
| Support Level | $1.17 | $1.63 |
| Resistance Level | $1.46 | $2.58 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 12.43 | 3.90 |
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.